• Je něco špatně v tomto záznamu ?

Automated Production of [68Ga]Ga-Desferrioxamine B on Two Different Synthesis Platforms

M. Kraihammer, M. Petřík, C. Rangger, M. Gabriel, H. Haas, B. Nilica, I. Virgolini, C. Decristoforo

. 2024 ; 16 (9) : . [pub] 20240921

Status neindexováno Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24017774

Grantová podpora
DOI: 10.55776/KLI909 FWF Austrian Science Fund

Background/Objectives: PET imaging of bacterial infection could potentially provide added benefits for patient care through non-invasive means. [68Ga]Ga-desferrioxamine B-a radiolabelled siderophore-shows specific uptake by human-pathogenic bacteria like Staphylococcus aureus or Pseudomonas aeruginosa and sufficient serum stability for clinical application. In this report, we present data for automated production of [68Ga]Ga-desferrioxamine B on two different cassette-based synthesis modules (Modular-Lab PharmTracer and GRP 3V) utilising commercially obtainable cassettes together with a licensed 68Ge/68Ga radionuclide generator. Methods: Quality control, including the determination of radiochemical purity, as well as a system suitability test, was set up via RP-HPLC on a C18 column. The two described production processes use an acetic acid/acetate buffer system with ascorbic acid as a radical scavenger for radiolabelling, yielding ready-to-use formulations with sufficient activity yield. Results: Batch data analysis demonstrated radiochemical purity of >95% by RP-HPLC combined with ITLC and excellent stability up to 2 h after synthesis. Specifications for routine production were set up and validated with four masterbatches for each synthesis module. Conclusions: Based on this study, an academic clinical trial for imaging of bacterial infection was initiated. Both described synthesis methods enable automated production of [68Ga]Ga-desferrioxamine B in-house with high reproducibility for clinical application.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24017774
003      
CZ-PrNML
005      
20241016081917.0
007      
ta
008      
241008s2024 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/pharmaceutics16091231 $2 doi
035    __
$a (PubMed)39339267
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Kraihammer, Martin $u Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria $u Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Krankenhausstrasse 9, A-4021 Linz, Austria $u Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, A-4040 Linz, Austria $1 https://orcid.org/0009000584671841
245    10
$a Automated Production of [68Ga]Ga-Desferrioxamine B on Two Different Synthesis Platforms / $c M. Kraihammer, M. Petřík, C. Rangger, M. Gabriel, H. Haas, B. Nilica, I. Virgolini, C. Decristoforo
520    9_
$a Background/Objectives: PET imaging of bacterial infection could potentially provide added benefits for patient care through non-invasive means. [68Ga]Ga-desferrioxamine B-a radiolabelled siderophore-shows specific uptake by human-pathogenic bacteria like Staphylococcus aureus or Pseudomonas aeruginosa and sufficient serum stability for clinical application. In this report, we present data for automated production of [68Ga]Ga-desferrioxamine B on two different cassette-based synthesis modules (Modular-Lab PharmTracer and GRP 3V) utilising commercially obtainable cassettes together with a licensed 68Ge/68Ga radionuclide generator. Methods: Quality control, including the determination of radiochemical purity, as well as a system suitability test, was set up via RP-HPLC on a C18 column. The two described production processes use an acetic acid/acetate buffer system with ascorbic acid as a radical scavenger for radiolabelling, yielding ready-to-use formulations with sufficient activity yield. Results: Batch data analysis demonstrated radiochemical purity of >95% by RP-HPLC combined with ITLC and excellent stability up to 2 h after synthesis. Specifications for routine production were set up and validated with four masterbatches for each synthesis module. Conclusions: Based on this study, an academic clinical trial for imaging of bacterial infection was initiated. Both described synthesis methods enable automated production of [68Ga]Ga-desferrioxamine B in-house with high reproducibility for clinical application.
590    __
$a NEINDEXOVÁNO
655    _2
$a časopisecké články $7 D016428
700    1_
$a Petřík, Miloš $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, CZ-77900 Olomouc, Czech Republic $1 https://orcid.org/0000000313345916
700    1_
$a Rangger, Christine $u Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria $1 https://orcid.org/0000000311679779
700    1_
$a Gabriel, Michael $u Institute of Nuclear Medicine and Endocrinology, Kepler University Hospital, Krankenhausstrasse 9, A-4021 Linz, Austria $u Medical Faculty, Johannes Kepler University Linz, Altenberger Strasse 69, A-4040 Linz, Austria
700    1_
$a Haas, Hubertus $u Institute of Molecular Biology, Biocenter, Medical University of Innsbruck, A-6020 Innsbruck, Austria $1 https://orcid.org/0000000324729878
700    1_
$a Nilica, Bernhard $u Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria
700    1_
$a Virgolini, Irene $u Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria $1 https://orcid.org/0000000170976170
700    1_
$a Decristoforo, Clemens $u Department of Nuclear Medicine, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria $1 https://orcid.org/0000000305664036
773    0_
$w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 16, č. 9 (2024)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39339267 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241008 $b ABA008
991    __
$a 20241016081912 $b ABA008
999    __
$a ok $b bmc $g 2196371 $s 1229725
BAS    __
$a 3
BAS    __
$a PreBMC-PubMed-not-MEDLINE
BMC    __
$a 2024 $b 16 $c 9 $e 20240921 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
GRA    __
$a DOI: 10.55776/KLI909 $p FWF Austrian Science Fund
LZP    __
$a Pubmed-20241008

Najít záznam

Citační ukazatele

Možnosti archivace